1812 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 7
Orwig et al.
(12) Delange, R. J.; Smith, E. L., Leucine Aminopeptidase and Other
N-Terminal Exopeptidases. In The Enzymes, 3rd ed.; Boyer, P. D.,
Ed.; Academic Press: New York, 1971; Vol. 3, pp 81-118.
(13) Lugrin, D.; Vecchini, F.; Doulut, S.; Rodriguez, M.; Martinez, J.;
Kitabgi, P. Reduced peptide bond pseudopeptide analogues of neu-
rotensin: binding and biological activities, and in vitro metabolic
stability. Eur. J. Pharmacol. 1991, 205 (2), 191–198.
(14) Heavner, G. A.; Kroon, D. J.; Audhya, T.; Goldstein, G. Biologically
active analogs of thymopentin with enhanced enzymatic stability.
Peptides 1986, 7 (6), 1015–1019.
(36) Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant
(Ki) and the concentration of inhibitor which causes 50% inhibition
(IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22 (23),
3099–3108.
(37) Aronin, N.; Carraway, R. E.; Ferris, C. F.; Hammer, R. A.; Leeman,
S. E. The stability and metabolism of intravenously administered
neurotensin in the rat. Peptides 1982, 3 (4), 637–642.
(38) Lee, Y. C.; Uttenthal, L. O.; Smith, H. A.; Bloom, S. R. In vitro
degradation of neurotensin in human plasma. Peptides 1986, 7 (3),
383–387.
(15) Powell, M. F. Peptide stability in drug development: in vitro peptide
degradation in plasma and serum. Annu. Rep. Med. Chem. 1993, 28,
285–294.
(16) Driessen, H. P.; Ramaekers, F. C.; Vree Egberts, W. T.; Dodemont,
H. J.; de Jong, W. W.; Tesser, G. I.; Bloemendal, H. The function of
N alpha-acetylation of the eye-lens crystallins. Eur. J. Biochem. 1983,
136 (2), 403–406.
(17) Stock, A.; Clarke, S.; Clarke, C.; Stock, J. N-Terminal methylation
of proteins: structure, function and specificity. FEBS Lett. 1987, 220
(1), 8–14.
(18) Bajusz, S.; Szell, E.; Bagdy, D.; Barabas, E.; Horvath, G.; Dioszegi,
M.; Fittler, Z.; Szabo, G.; Juhasz, A.; Tomori, E.; et al. Highly active
and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide
aldehyde prone to spontaneous inactivation, and its stable N-methyl
derivative, D-MePhe-Pro-Arg-H. J. Med. Chem. 1990, 33 (6), 1729–
1735.
(39) Checler, F.; Barelli, H.; Kitabgi, P.; Vincent, J. P. Neurotensin
metabolism in various tissues of central and peripheral origins:
ubiquitous involvement of a novel neurotensin degrading metalloen-
dopeptidase. Biochimie 1988, 70 (1), 75–82.
(40) Checler, F.; Vincent, J. P.; Kitabgi, P. Inactivation of neurotensin by
rat brain synaptic membranes partly occurs through cleavage at the
Arg8-Arg9 peptide bond by a metalloendopeptidase. J. Neurochem.
1985, 45 (5), 1509–1513.
(41) Checler, F.; Vincent, J. P.; Kitabgi, P. Degradation of neurotensin by
rat brain synaptic membranes: involvement of a thermolysin-like
metalloendopeptidase (enkephalinase), angiotensin-converting enzyme,
and other unidentified peptidases. J. Neurochem. 1983, 41 (2), 375–
384.
(42) McDermott, J. R.; Smith, A. I.; Edwardson, J. A.; Griffiths, E. C.
Mechanism of neurotensin degradation by rat brain peptidases. Regul.
Pept. 1982, 3 (5-6), 397–404.
(19) Marschutz, M. K.; Zauner, W.; Mattner, F.; Otava, A.; Buschle, M.;
Bernkop-Schnurch, A. Improvement of the enzymatic stability of a
cytotoxic T-lymphocyte-epitope model peptide for its oral administra-
tion. Peptides 2002, 23 (10), 1727–1733.
(20) Lundquist, J. T. I. V.; Dix, T. A. Synthesis and human neurotensin
receptor binding activities of Neurotensin(8-13) analogs containing
position 8 a-azido-N-alkylated derivatives of ornithine, lysine, and
homolysine. J. Med. Chem. 1999, 42 (23), 4914–4918.
(21) Kokko, K. P.; Hadden, M. K.; Orwig, K. S.; Mazella, J.; Dix, T. A.
In vitro analysis of stable, receptor-selective neurotensin(8-13)
analogues. J. Med. Chem. 2003, 46 (19), 4141–4148.
(22) Hadden, M. K.; Orwig, K. S.; Kokko, K. P.; Mazella, J.; Dix, T. A.
Design, synthesis, and evaluation of the antipsychotic potential of
orally bioavailable neurotensin(8-13) analogues containing non-
natural arginine and lysine residues. Neuropharmacology 2005, 49
(8), 1149–1159.
(23) Boules, M.; Shaw, A.; Fredrickson, P.; Richelson, E. Neurotensin
agonists: potential in the treatment of schizophrenia. CNS Drugs 2007,
21 (1), 13–23.
(43) Bruehlmeier, M.; Garayoa, E. G.; Blanc, A.; Holzer, B.; Gergely, S.;
Tourwe, D.; Schubiger, P. A.; Blauenstein, P. Stabilization of
neurotensin analogues: effect on peptide catabolism, biodistribution
and tumor binding. Nuclear Med. Biol. 2002, 29 (3), 321–327.
(44) Garcia-Garayoa, E.; Allemann-Tannahill, L.; Blauenstein, P.; Will-
mann, M.; Carrel-Remy, N.; Tourwe, D.; Iterbeke, K.; Conrath, P.;
Schubiger, P. A. In vitro and in vivo evaluation of new radiolabeled
neurotensin(8-13) analogues with high affinity for NT1 receptors.
Nucl. Med. Biol. 2001, 28 (1), 75–84.
(45) Vincent, J. P. Neurotensin receptors: binding properties, transduction
pathways, and structure. Cell. Mol. Neurobiol. 1995, 15 (5), 501–
512.
(46) Vincent, J. P.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin
receptors. Trends Pharmacol. Sci. 1999, 20 (7), 302–309.
(47) Dubuc, I.; Sarret, P.; Labbe-Jullie, C.; Botto, J. M.; Honore, E.;
Bourdel, E.; Martinez, J.; Costentin, J.; Vincent, J. P.; Kitabgi, P.;
Mazella, J. Identification of the receptor subtype involved in the
analgesic effect of neurotensin. J. Neurosci. 1999, 19 (1), 503–510.
(48) Pettibone, D. J.; Hess, J. F.; Hey, P. J.; Jacobson, M. A.; Leviten, M.;
Lis, E. V.; Mallorga, P. J.; Pascarella, D. M.; Snyder, M. A.; Williams,
J. B.; Zeng, Z. The effects of deleting the mouse neurotensin receptor
NTR1 on central and peripheral responses to neurotensin. J. Phar-
macol. Exp. Ther. 2002, 300 (1), 305–313.
(49) Remaury, A.; Vita, N.; Gendreau, S.; Jung, M.; Arnone, M.; Poncelet,
M.; Culouscou, J. M.; Le Fur, G.; Soubrie, P.; Caput, D.; Shire, D.;
Kopf, M.; Ferrara, P. Targeted inactivation of the neurotensin type 1
receptor reveals its role in body temperature control and feeding
behavior but not in analgesia. Brain Res. 2002, 953 (1-2), 63–72.
(50) Bouvier, M.; Guo, H. C.; Smith, K. J.; Wiley, D. C. Crystal structures
of HLA-A*0201 complexed with antigenic peptides with either the
amino- or carboxyl-terminal group substituted by a methyl group.
Proteins 1998, 33 (1), 97–106.
(51) Kitabgi, P.; Poustis, C.; Granier, C.; Van Rietschoten, J.; Rivier, J.;
Morgat, J. L.; Freychet, P. Neurotensin binding to extraneural and
neural receptors: comparison with biological activity and structure-
activity relationships. Mol. Pharmacol. 1980, 18 (1), 11–19.
(52) Mills, A.; Demoliou-Mason, C. D.; Barnard, E. A. Characterization
of neurotensin binding sites in intact and solubilized bovine brain
membranes. J. Neurochem. 1988, 50 (3), 904–911.
(53) Tyler, B. M.; Douglas, C. L.; Fauq, A.; Pang, Y. P.; Stewart, J. A.;
Cusack, B.; McCormick, D. J.; Richelson, E. In vitro binding and
CNS effects of novel neurotensin agonists that cross the blood-brain
barrier. Neuropharmacology 1999, 38 (7), 1027–1034.
(24) Dobner, P. R. Neurotensin and pain modulation. Peptides 2006, 27
(10), 2405–2414.
(25) Okarvi, S. M. Peptide-based radiopharmaceuticals and cytotoxic
conjugates: potential tools against cancer. Cancer Treat. ReV. 2008,
34 (1), 13–26.
(26) Akunne, H. C.; Demattos, S. B.; Whetzel, S. Z.; Wustrow, D. J.; Davis,
D. M.; Wise, L. D.; Cody, W. L.; Pugsley, T. A.; Heffner, T. G.
Agonist properties of a stable hexapeptide analog of neurotensin, N
alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1). Biochem. Pharmacol.
1995, 49 (8), 1147–1154.
(27) Kennedy, K. J.; Orwig, K. S.; Dix, T. A.; Christopher, J.; Jaffa, A. A.
Synthesis and analysis of potent, more lipophilic derivatives of the
bradykinin B2 receptor antagonist peptide Hoe 140. J. Pept. Res. 2002,
59 (4), 139–148.
(28) Carpino, L. A.; Han, G. Y. 9-Fluorenylmethoxycarbonyl amino-
protecting group. J. Org. Chem. 1972, 37 (22), 3404–3409.
(29) Kennedy, K. J.; Lundquist, I.; Joseph, T.; Simandan, T. L.; Beeson,
C. C.; Dix, T. A. Asymmetric synthesis of non-natural homologues
of lysine. Bioorg. Med. Chem. Lett. 1997, 7 (14), 1937–1940.
(30) Orwig, K. S.; Dix, T. A. Synthesis of C-alpha methylated carboxylic
acids: isosteres of arginine and lysine for use as N-terminal capping
residues in polypeptides. Tetrahedron Lett. 2005, 46 (41), 7007–7009.
(31) Lundquist, J. T. I. V.; Pelletier, J. C. Improved solid-phase peptide
synthesis method utilizing a-azide-protected amino acids. Org. Lett.
2001, 3 (5), 781–783.
(32) Evans, D. A.; Britton, T. C.; Ellman, J. A. Contrasteric carboximide
hydrolysis with lithium hydroperoxide. Tetrahedron Lett. 1987, 28
(49), 6141–6144.
(33) Lee, H.-S.; LePlae, P. R.; Porter, E. A.; Gellman, S. H. An Efficient
Route to Either Enantiomer of Orthogonally Protected trans-3-
Aminopyrrolidine-4-carboxylic Acid. J. Org. Chem. 2001, 66 (10),
3597–3599.
(54) Amar, S.; Kitabgi, P.; Vincent, J. P. Activation of phosphatidylinositol
turnover by neurotensin receptors in the human colonic adenocarci-
noma cell line HT29. FEBS Lett. 1986, 201 (1), 31–36.
(55) Vincent, J. P.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin
receptors. Trends Pharmacol. Sci. 1999, 20 (7), 302–309.
(56) Gully, D.; Canton, M.; Boigegrain, R.; Jeanjean, F.; Molimard, J. C.;
Poncelet, M.; Gueudet, C.; Heaulme, M.; Leyris, R.; Brouard, A.; et
al. Biochemical and pharmacological profile of a potent and selective
nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad.
Sci. U.S.A. 1993, 90 (1), 65–69.
(34) Miller, S. C.; Scanlan, T. S. Site-Selective N-Methylation of Peptides
on Solid Support. J. Am. Chem. Soc. 1997, 119 (9), 2301–2302.
(35) Kokko, K. P.; Dix, T. A. Monitoring neurotensin(8-13) degradation
in human and rat serum utilizing matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry. Anal. Biochem. 2002, 308
(1), 34–41.
(57) Oury-Donat, F.; Thurneyssen, O.; Gonalons, N.; Forgez, P.; Gully,
D.; Le Fur, G.; Soubrie, P. Characterization of the effect of SR48692
on inositol monophosphate, cyclic GMP and cyclic AMP responses
linked to neurotensin receptor activation in neuronal and non-neuronal